{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:58:49Z","timestamp":1780325929899,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["YGLX202315"],"award-info":[{"award-number":["YGLX202315"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016126","name":"Beijing Hospitals Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7242075"],"award-info":[{"award-number":["7242075"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:20:45Z","timestamp":1708014045000},"page":"130-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study"],"prefix":"10.1016","volume":"236","author":[{"given":"Li","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-juan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-qiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-qing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-hua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.02.011_bb0005","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.thromres.2022.01.008","article-title":"Venous thromboembolism and risk stratification in hematological malignancies","volume":"213","author":"Sanfilippo","year":"2022","journal-title":"Thromb. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.02.011_bb0010","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0049-3848(20)30401-1","article-title":"Assessing the risk of venous thromboembolism in multiple myeloma","volume":"191","author":"Sanfilippo","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.02.011_bb0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/hematology.2022000414","article-title":"Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy","volume":"2022","author":"Covut","year":"2022","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.011_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bjh.19056","article-title":"Venous thromboembolism in multiple myeloma: increasing evidence in support of direct oral anticoagulants","volume":"203","author":"Swan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.011_bb0030","first-page":"1","article-title":"Thrombosis in multiple myeloma: mechanisms, risk assessment and management","author":"Jarchowsky","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.011_bb0035","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.011_bb0040","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.011_bb0045","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0050","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.011_bb0055","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11239-023-02817-7","article-title":"Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort","volume":"56","author":"da Costa","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.011_bb0065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12959-023-00534-y","article-title":"Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma","volume":"21","author":"Li","year":"2023","journal-title":"Thromb. J."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.011_bb0075","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.2022017517","article-title":"VTE prophylaxis in multiple myeloma","volume":"140","author":"Falanga","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.011_bb0080","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s10238-023-01080-7","article-title":"Thrombosis events in Chinese patients with newly diagnosed multiple myeloma","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.011_bb0090","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.011_bb0095","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.bbmt.2019.06.032","article-title":"Venous thromboembolism in autologous blood or marrow transplantation survivors: a report from the blood or marrow transplant survivor study","volume":"25","author":"Gangaraju","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.011_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.011_bb0105","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.011_bb0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.011_bb0115","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00432-021-03693-5","article-title":"Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study","volume":"148","author":"Leclerc","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.011_bb0120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.011_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma","volume":"40","author":"De Stefano","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"issue":"24","key":"10.1016\/j.thromres.2024.02.011_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246216","article-title":"Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma","volume":"14","author":"Fotiou","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2024.02.011_bb0135","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S0049-3848(10)70024-4","article-title":"Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma","volume":"125","author":"Wun","year":"2010","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.011_bb0140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.011_bb0145","article-title":"Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents","volume":"9","author":"Kahale","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.011_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2009.23.0169","article-title":"Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone","volume":"28","author":"Zangari","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.011_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:18:07Z","timestamp":1717251487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482400046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"alternative-id":["S004938482400046X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}